The world continues to face the challenges of the global threat from COVID-19, and we at ALTURiX continue to do everything we can to play our part in helping to overcome this challenge.
The ALTURiX mission is to provide medicines value, and to do so reliably to help the NHS improve patient outcomes.
We know that several of our products are extremely important in the management of critically ill patients, and our first priority is to take every possible step to maintain the supply of these medicines to patients and healthcare professionals.
Phosphate and potassium levels are known to be difficult to maintain in ITU patients requiring mechanical ventilation1. Retrospective analyses from a Critical Care Unit in China have shown that phosphate levels are lower in COVID-19 patients even before they are ventilated and decrease even further in patients with more severe symptoms2.
Hypokalaemia has also been found in the vast majority of critically ill COVID-19 patients due to potassium loss through the kidney3. The consequences of these findings are not yet known but the close monitoring of potassium and phosphate levels in COVID-19 patients, and appropriate correction, is suggested to be of some importance.
Additionally, N-Acetylcysteine is being used globally to help in the treatment of COVID-19 patients, with studies ongoing to evaluate the precise benefit it can provide4.
We take our responsibility to reliably provide these important medicines to the NHS frontline extremely seriously. We are working closely with the Department of Health to ensure that UK patients are prioritised, and we are vigilant to any Supply Chain disruption which may impact this approach.
As each day brings emerging challenges for us all, please be assured that we will continue to do everything we can as a company to ensure that we can continue to serve those who rely on our products.
Please use the Contact Us page if you would like any further information relating to this news item or would like a member of the team to get in touch.
2. Correlation between hypophosphatemia and the severity of Coronavirus Disease 2019 patients
Xiaobo X, et al Link
3. Hypokalaemia and Clinical Implications in Patients with Coronavirus Disease 2019 (COVID-19) Chen D, et al. Link
4. World Health Organisation International Clinical Trials Registry Platform (ICTRP). Link